Stifel analyst Jonathan Block raised the firm’s price target on Inspire Medical to $350 from $300 and keeps a Buy rating on the shares, citing what it sees as the potential for Q2 revenue upside and 2024 revenue outperformance assuming more “normalized” utilization rates.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INSP:
- Inspire Medical Systems, Inc. to Report Second Quarter 2023 Financial Results on August 1, 2023
- Inspire Medical price target raised to $355 from $310 at BofA
- Inspire Medical Systems, Inc. Announces FDA Approval for Apnea Hypopnea Index Indication Expansion and Increased Body Mass Index Labeling
- Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2023 Medtech Innovation Spotlight Series